Earlier versions of a spending cuts package passed through Congress targeted PEPFAR. But the White House, concerned about ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

Adults who switched from daily ART to long-acting cabotegravir-rilpivirine showed high levels of virologic suppression, high ...

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

The investigational oral pre-exposure prophylaxis (PrEP) agent MK-8527 showed a similar, well-tolerated safety profile to ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...

The federal government has been forced to restore $6.2 million in funding to LGBTQ+ and HIV organizations.

PEPFAR was launched in 2003 to stop the spread of HIV in Africa. Now, although some funding remains for the program, many of ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

After the virologic failure of cabotegravir/rilpivirine and despite dual-class resistance mutations, Canadian doctors have ...